Published in final edited form as:

Infect Control Hosp Epidemiol. 2013 August ; 34(8): 847–849. doi:10.1086/671269.

Is the Use of Antimicrobial Devices to Prevent Infection Correlated Across Different Healthcare-Associated Infections? Results from a National Survey

Sanjay Saint, MD, MPH^{1,2,3}, M. Todd Greene, PhD, MPH^{2,3}, Laura Damschroder, MS, MPH¹, and Sarah L. Krein, PhD, RN^{1,2,3}

¹VA Ann Arbor Healthcare System and the Hospital Outcomes Program of Excellence (HOPE), Department of Veterans Affairs (VA), Ann Arbor, MI, USA

²Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA

³VA/UM Patient Safety Enhancement Program, Ann Arbor, MI, USA

Abstract

Antimicrobial devices are often used to prevent nosocomial infection despite mixed evidence. Using a national survey, we found that a hospital's use of an antimicrobial device to prevent one type of infection was associated with a higher likelihood that a similar device would be used to prevent a different infection.

Keywords

Healthcare-associated infection; patient safety; antimicrobial devices; survey

Background

Healthcare-associated infections due to the use of devices – such as urinary catheters, central venous catheters, or endotracheal tubes – are especially common and morbid. One approach to preventing infection is using devices that have a coating of antimicrobial substances. However, this approach is controversial because the evidence supporting the use of such antimicrobial devices is mixed and dependent on the device: generally strong for antimicrobial central venous catheters, generally weak for antimicrobial urinary catheters, and unclear for antimicrobial endotracheal tubes.^{1–3} Despite their higher cost, the use of some antimicrobial devices is substantial with almost half of U.S. hospitals reporting regular use of antimicrobial urinary catheters and about one third reporting regular use of antimicrobial central venous catheters.⁴

We explored whether a hospital's use of a coated device to prevent one type of infection – such as using an antimicrobial central venous catheter to prevent central line-associated

Corresponding Author: Sanjay Saint, MD, MPH, George Dock Professor of Internal Medicine, University of Michigan Medical School, 2800 Plymouth Road, Building 16, Room 433W, Ann Arbor, MI 48109-2800, Phone: (734) 615-8341, Fax: (734) 936-8944, saint@med.umich.edu.

Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.

Potential Conflicts of Interest. SS has received numerous honoraria and speaking fees from academic medical centers, hospitals, group-purchasing organizations (e.g., Premier, VHA), specialty societies, state-based hospital associations, and non-profit foundations (e.g., Michigan Health and Hospital Association, Institute for Healthcare Improvement) for lectures about catheter-associated urinary tract infection, implementing change, and leadership. No other potential conflict of interest is noted.

bloodstream infection (CLABSI) – was associated with a higher likelihood that a similar type of device would be used to prevent a *completely different* infection (e.g., antimicrobial urinary catheters to prevent catheter-associated urinary tract infection (CAUTI)).

Methods

Study Design and Data Collection

We conducted a national survey to compare the use of specific infection prevention practices by U.S. hospitals. In March 2009, using a national sample of non-federal hospitals, we surveyed infection prevention personnel to understand how often their hospital used specific practices to prevent CAUTI, CLABSI, and ventilator-associated pneumonia (VAP). Our sample had been originally derived for a similar survey study conducted in 2005.⁵ We identified all non-federal, general medical and surgical hospitals with an intensive care unit and at least 50 hospital beds using the 2005 American Hospital Association DatabaseTM (fiscal year 2003 data). We then stratified hospitals into 2 bed size groups (50–250 beds and 251 beds), and selected a random sample of 300 hospitals from each group. We sent the survey out to a total of 588 non-federal hospitals. Following a modified Dillman approach, we sent an initial mailing, a reminder letter, and a second mailing of the survey after 4 weeks to those who had not yet responded. A third survey mailing was added in 2009 due to a lower response to the first two mailings, which had occurred contemporaneous with H1N1 preparations. All mailings were addressed to the “Infection Control Coordinator.” The University of Michigan and VA Ann Arbor Healthcare System provided institutional review board approval.

Study Measures

The survey asked about the use of practices for adult acute care patients to prevent CAUTI, CLABSI, and VAP, with a specific focus on practices identified in published guidelines or recommendations from the Centers for Disease Control and Prevention (CDC) or professional societies.^{1–3} Respondents were asked to rate the frequency of use for each practice on a scale from 1 to 5 (1 being never and 5 always). For our analysis, “regular use” was defined as receiving a rating of 4 or 5 indicating the practice was used almost always or always. For this manuscript, we examined the relationships between: antimicrobial urinary catheters (silver-alloy or nitrofurazone-releasing) and antimicrobial central venous catheters (chlorhexidine/silver sulfadiazine or minocycline-rifampin); antimicrobial urinary catheters and silver-coated endotracheal tubes; and antimicrobial central venous catheters and silver-coated endotracheal tubes.

Statistical Analysis

Logistic regression models were fit to examine multivariable relationships between the selected infection prevention practices, while accounting for the following potentially confounding characteristics: number of years the respondent has been in his or her current position, the number of full-time equivalent infection preventionists, and hospital bed-size. All analyses were conducted using Stata version 11.0 (Stata Corp, LP).

Results

A total of 406 hospitals responded for an overall response rate of 69%. Reported “regular use” for antimicrobial devices varied by clinical domain. For CAUTI, antimicrobial urinary catheters were reported to be regularly used in 45% of hospitals. For CLABSI, 33% reported regularly using antimicrobial central venous catheters. For VAP, 5% of hospitals reported regularly using silver-coated endotracheal tubes.

The regular use of one type of antimicrobial device in one clinical domain was significantly associated with the use of another type of antimicrobial device in several different clinical domains. Regularly using antimicrobial central venous catheters was associated with a nearly 3-fold increase (OR =2.57; 95% CI:1.64 – 4.01; $p<0.001$) in the odds of regularly using antimicrobial urinary catheters. Regularly using silver-coated endotracheal tubes to prevent VAP was associated with over 4-fold increases in the odds of regularly using antimicrobial urinary catheters (OR =4.51; 95% CI:1.44 – 14.09; $p<0.001$) and antimicrobial central venous catheters (OR =4.57; 95% CI:1.64 – 12.74; $p<0.001$).

Discussion

Based on a national survey of self-reported use of infection prevention practices, we found that hospitals regularly using antimicrobial devices for the prevention of one device-related infection were more likely to use similar devices for the prevention of another type of infection. The correlation of using antimicrobial devices across the clinical domains of CAUTI, CLABSI, and VAP prevention was striking.

Although previous studies have shown clinical benefits of using antimicrobial urinary catheters to prevent bacteriuria,⁶ a recent randomized trial reported no clinically significant benefit in reducing symptomatic CAUTI.⁷ Although a recent trial has found that silver-coated endotracheal tubes reduced VAP rates,⁸ the benefit of antimicrobial endotracheal tubes is considered an unresolved issue.³ Multiple randomized trials, however, have shown that use of antimicrobial devices appear to prevent CLABSI.² This level of evidence may lead some hospital staff toward a general predisposition to using antimicrobial devices to prevent infection across multiple clinical domains. Another possible explanation is that it is relatively easy to implement coated devices; a matter of “swapping” uncoated devices with coated ones. Despite the additional cost, for some hospitals, this cost may be perceived as a bargain compared with the challenges in implementing or improving other more complex infection prevention processes such as instituting nurse-initiated urinary catheter discontinuation to reduce CAUTI, which requires changes in behaviors of staff across multiple roles and professions.⁹ Another possible factor is the role of costing and marketing strategies by device vendors in some hospitals.¹⁰ These types of contextual insights may help guide future implementation efforts within infection prevention.

Our study has several limitations. First, since the response rate was less than 100%, our results have some susceptibility to non-response bias. Second, we relied on self-reported data from the lead infection preventionist at each hospital to determine how frequently the various prevention practices were used. Although an individual respondent may have overstated or understated how frequently the various practices were used, we have no reason to believe this would happen systematically. Third, by virtue of our study design, we are unfortunately unable to correlate utilization data with effectiveness data.

Our findings may help efforts to implement evidence-based infection prevention practices in hospitals. It appears that some hospitals have a proclivity to use antimicrobial devices across different clinical domains, despite the overall mixed evidence-base supporting their use. More expensive is not necessarily better, and it is possible that some hospitals are relying on the potential benefits of antimicrobial devices with inadequate attention paid to basic infection prevention measures.

Acknowledgments

We thank Christine Kowalski, MPH, for data collection, and Andrew Hickner, MSI, for help with manuscript preparation.

Financial support. SS received grant support from the Blue Cross Blue Shield of Michigan Foundation. SS and SK received grant support from the National Institute of Nursing Research [5 R01 NR010700].

References

1. Gould CV, Umscheid CA, Agarwal RK, Kuntz G, Pegues DA. Healthcare Infection Control Practices Advisory Committee. Guideline for prevention of catheter-associated urinary tract infections 2009. *Infect Control Hosp Epidemiol.* 2010; 31(4):319–326. [PubMed: 20156062]
2. O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. *Clin Infect Dis.* 2011; 52(9):e162–93. [PubMed: 21460264]
3. Coffin SE, Klompas M, Classen D, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. *Infect Control Hosp Epidemiol.* 2008; 29 (Suppl 1):S31–40. [PubMed: 18840087]
4. Krein SL, Kowalski CP, Hofer TP, Saint S. Preventing hospital-acquired infections: a national survey of practices reported by u.s. Hospitals in 2005 and 2009. *J Gen Intern Med.* 2012; 27(7): 773–779. [PubMed: 22143455]
5. Saint S, Kowalski CP, Kaufman SR, et al. Preventing hospital-acquired urinary tract infection in the United States: a national study. *Clin Infect Dis.* 2008; 46(2):243–250. [PubMed: 18171256]
6. Schumm K, Lam TB. Types of urethral catheters for management of short-term voiding problems in hospitalised adults. *Cochrane Database Syst Rev.* 2008; 2(2):CD004013. [PubMed: 18425896]
7. Pickard R, Lam T, MacLennan G, et al. Antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term catheterisation in hospital: a multicentre randomised controlled trial. *Lancet.* 2012; 380(9857):1927–1935. [PubMed: 23134837]
8. Kollef MH, Afessa B, Anzueto A, et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. *JAMA.* 2008; 300(7):805–813. [PubMed: 18714060]
9. Damschroder LJ, Banaszak-Holl J, Kowalski CP, Forman J, Saint S, Krein SL. The role of the champion in infection prevention: results from a multisite qualitative study. *Qual Saf Health Care.* 2009; 18(6):434–440. [PubMed: 19955453]
10. Saint S, Kowalski CP, Forman J, et al. A multicenter qualitative study on preventing hospital-acquired urinary tract infection in US hospitals. *Infect Control Hosp Epidemiol.* 2008; 29(4):333–341. [PubMed: 18462146]